Comparative Pharmacology
Head-to-head clinical analysis: DIENESTROL versus OGEN 1 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIENESTROL versus OGEN 1 25.
DIENESTROL vs OGEN 1.25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic nonsteroidal estrogen that binds to estrogen receptors, activating transcription of estrogen-responsive genes, leading to effects similar to endogenous estrogens.
Estrogen replacement therapy; binds to estrogen receptors (ERα and ERβ), modulating gene transcription and exerting effects on reproductive tissues, bone density, and cardiovascular system.
0.1 to 0.5 mg orally once daily for estrogen replacement therapy; 0.5 to 1.0 mg orally once daily for prostatic carcinoma.
1.25 mg orally once daily for 3 weeks, followed by a 1-week rest period; cyclic therapy.
None Documented
None Documented
Terminal elimination half-life is approximately 24-48 hours, longer with hepatic impairment.
Clinical Note
moderateDienestrol + Etoricoxib
"Dienestrol may increase the thrombogenic activities of Etoricoxib."
Clinical Note
moderateDienestrol + Parecoxib
"Dienestrol may increase the thrombogenic activities of Parecoxib."
Clinical Note
moderateDienestrol + Voriconazole
"The metabolism of Voriconazole can be decreased when combined with Dienestrol."
Clinical Note
moderateDienestrol + Lumiracoxib
"Dienestrol may increase the thrombogenic activities of Lumiracoxib."
Terminal elimination half-life: 10–24 hours (mean ~15 h); clinically, steady-state achieved in 5–7 days
Primarily renal (40-60% as glucuronide conjugates) and biliary/fecal (30-50% with enterohepatic recycling).
Renal: 95% (as glucuronide and sulfate conjugates); biliary/fecal: ~5%
Category C
Category C
Estrogen
Estrogen